Modapil, Mohadjer .

HRN: 23-35-40  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/17/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
07/17/2023
07/23/2023
IVT
23mg
Od
Neonatal Sepsis
Waiting Final Action 
07/17/2023
AMPICILLIN 1GM (VIAL)
07/17/2023
07/23/2023
IVT
75 Mg
Q12
Neonatal Sepsis
Waiting Final Action 
07/17/2023
CEFOTAXIME 500MG (VIAL)
07/17/2023
07/23/2023
IVT
150mg
Now Then Q12
Neonatal Sepsis
Waiting Final Action 
07/18/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
07/18/2023
07/24/2023
IVTT
22.5mg LD
Q8h
Neonatal Sepsis
Checking Final Appropriateness 
07/18/2023
AMPICILLIN 250MG (VIAL)
07/18/2023
07/24/2023
IVTT
100mg
Q12
Neonatal Sepsis
Checking Final Appropriateness 
07/25/2023
CEFOTAXIME 500MG (VIAL)
07/25/2023
08/06/2023
IVTT
150mg
Q12
Neonatal Sepsis
Checking Final Appropriateness 
07/25/2023
CEFOTAXIME 500MG (VIAL)
07/25/2023
08/16/2023
IVTT
150mg
Q12
Neonatal Sepsis
Checking Final Appropriateness 
07/25/2023
AMPICILLIN 1GM (VIAL)
07/25/2023
08/06/2023
IVTT
100mg
Q12
Neonatal Sepsis
Checking Final Appropriateness 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: